Eric Wilkinson is a biotechnology executive and scientist with over 37 years of increasing responsibility in executive management, R&D, IP development and management, partnering and licensing, and business development. Over the course of his career he has developed and commercialized a number of technologies and products. Eric is experienced in both domestic and international markets. He has founded or co-founded more than 10 biotechnology companies, served as President/CEO of 6 companies with direct P&L responsibility and has served on Boards of Directors of both public and private companies. He also has extensive experience in corporate consulting and advisement focusing in finance (debt, equity, VC, private), M&A, in/out-licensing of technology, and public offerings. Eric's R&D experience includes monoclonal antibody and vaccine development at IDEC Pharmaceuticals (now Biogen IDEC), creation of a subsidiary company in the Cleveland Clinic doing high throughput genomic typing for tissue transplantation and infectious disease testing, and high throughput genomic testing in Norway for a large-scale juvenile diabetes study. In the early 2000’s he served as Vice President of Life Sciences at XL TechGroup and Managing Director of DxTech, a subsidiary company, until its over $1.2 billion public offering in 2006. For the past decade Eric has been focused on development and growth of startup biotech and medtech companies in South East Asia, based in Singapore and Thailand.